29 March 2011 – Specialist global Contract Research Organisation (CRO), Phlexglobal has today announced it has completed a private equity-backed management buyout (MBO).
The deal with mid-market private equity investor, Inflexion Private Equity, will allow the company to further expand its provision of clinical trial support, a significant part of which is the management of global trial master files (TMF), both paper and electronic. The recent launch of version 3 of PhlexEview, the company’s eTMF solution, will underpin this growth.
The Phlexglobal management team remains largely the same with Phlexglobal’s former financial director, Stella Donoghue, moving into the role of managing director and Karen Redding remaining as global business development manager. They will be joined by technical director, John Lazenby and Sarah Tucker, who has been internally appointed as director of eTMF operations.